Although the frequency of TP53 mutations in AML patients is approximately 10%, for patients with complex karyotypes, or who were previously exposed to chemotherapy for the treatment of other malignancies, it jumps to over 40%. This evidence concerns the gene TP53 and acute myeloid leukemia.